Breaking News

Cellular Biomedicine Expands into Arthritis Market

June 13, 2013

Gets IP go-ahead for Chinese market

Cellular Biomedicine Group, a biopharma firm engaged in the development of treatments for degenerative and cancerous diseases, plans to expand into the China Osteoarthritis and Rheumatoid Arthritis market. Following a complete analysis of current China patents by an intellectual property law firm, Cellular Biomedicine Group has clearance to pursue IP operation with respect to its patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.
 
Dr. Wei (William) Cao, president of Cellular Biomedicine Group, said, "In China there are 72.5 million people suffering from knee osteoarthritis (KOA), and 4.5 million suffering from rheumatoid arthritis (RA). We are very confident to enter the world's largest KOA and RA market with freedom of operation."

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.